Program
Lymphodepleting chemotherapy
Its studies are mostly in Small Cell Lung Carcinoma · Neoplasms · Carcinoma, Ovarian Epithelial, led by Beijing Biotech.
Furthest: phase 2, since Mar 14, 20263 company-led studies, 3 open or runningNext primary completion: Feb 14, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biotech | 33 open or running | phase 2since Mar 14, 2026 | Mar 14, 2026 | Feb 14, 2027phase 2 · NCT07744256 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 14, 2026First studies: 2 phase 2 studiesFirst studyNCT07480954, NCT07510828
- Jul 30, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07744256 · 60 planned · China
Ahead
- Feb 14, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07744256
- Feb 17, 2027Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT07480954
- Mar 14, 2027Primary completion: phase 2 study in NeoplasmsNCT07510828
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07744256Small Cell Lung Carcinoma · China | 2 | Recruiting | Feb 14, 2027 | 60 |
| NCT07510828Neoplasms · China | 2 | Recruiting | Mar 14, 2027 | 60 |
| NCT07480954Carcinoma, Ovarian Epithelial · China | 2 | Recruiting | Feb 17, 2027 | 36 |
How it is read
Names in the registry
- “Lymphodepleting chemotherapy”, 3 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
- Neoplasms, 1 study
- Carcinoma, Ovarian Epithelial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.